Business context and reporting period
This summary covers the unaudited quarter ended March 31, 2014. The supplied filing is for iGambit Inc., not Nutex Health Inc.; verify the issuer and filing before relying on this summary. iGambit was a holding company whose operating subsidiary, Gotham Innovation Lab, provided media technology services to real estate agents and brokers. Management said it was shifting Gotham away from customer technical services toward real estate photography while seeking to expand operations and pursue acquisitions.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 or prior date |
|---|---|---|
| Revenue | $240,213 | $362,821 |
| Gross profit (margin) | $137,301 (57.2%) | $247,051 (68.1%) |
| General and administrative expense | $272,267 | $449,027 |
| Operating loss | $(134,966) | $(201,976) |
| Net loss | $(161,578) | $(202,614) |
| Cash from operations | $2,875 net, including $37,500 from discontinued operations; continuing operations used $34,625 | $(58,310) |
| Cash and cash equivalents | $28,607 | $26,870 at Dec. 31, 2013 |
| Current assets / current liabilities | $997,961 / $627,495 | $1,050,746 / $515,155 at Dec. 31, 2013 |
| Total liabilities | $627,495 | $515,155 at Dec. 31, 2013 |
| Stockholders’ equity | $394,609 | $556,187 at Dec. 31, 2013 |
Gross margin contracted by about 10.9 percentage points. Revenue fell about 33.8%, while G&A expense declined about 39.4%; the net loss narrowed about 20.3%. The filing reports basic and diluted loss per share of $0.01 in both quarters. Investing activities used $4,738 and financing activities provided $3,600 in Q1 2014. No long-term liabilities were reported.
Material changes, liquidity, and capital
- Management attributed lower revenue primarily to the Gotham customer technical services transition and lower expense partly to reduced payroll and Gotham operating costs. Cost of sales also declined with lower outsourced photography vendor costs.
- Accounts payable rose to $397,069 from $316,566 at year-end. The quarter-end balance sheet included a $74,750 net convertible note and a $152,076 derivative liability. The note’s stated principal was $103,500; its 8% terms allowed conversion at a substantial discount to market, and $34,500 of debt discount amortization was recorded during the quarter.
- Management said available capital was adequate for current operations, but anticipated private-market fundraising if expansion or acquisitions required it; it gave no quantified forecast and said funding was not assured. Cash was limited, and continuing operating activities consumed cash.
- At March 31, assets included $229,779 due under the IGX rescission agreement and $612,070 of net assets from discontinued operations, principally Digi-Data receivables and accrued interest. Their collection and timing are important to liquidity.
Outlook, risks, contingencies, and unusual items
- Management intended to grow Gotham and seek acquisition opportunities, but provided no numerical guidance. It cautioned that results may fluctuate and cited regulation, technology change, competition, and difficulty raising capital as risks.
- One customer represented approximately 65% of Gotham’s Q1 2014 sales and 62% of its accounts receivable, creating significant customer concentration.
- iGambit obtained a December 2013 summary judgment against Digi-Data for $570,590 plus interest. A February 2014 forbearance agreement set a $646,668.67 settlement amount with interest and staged payments. The filing states Digi-Data paid the full judgment balance plus accrued interest on May 12, 2014, after quarter-end.
- After quarter-end, the convertible noteholder converted $22,000 of principal into 203,797 shares; the filing states $81,500 of principal remained. The May 14 cover page reports 25,247,853 shares outstanding, versus 25,044,056 at March 31.
- A financial adviser claimed a $300,000 fee related to the rescinded IGX transaction; the company disputed that the fee was earned. Management said the outcome was not determinable but did not expect a material adverse effect.
- The statements are interim and omit information required for complete GAAP financial statements. The company recorded a full valuation allowance against deferred tax assets. Management reported disclosure controls effective, though the discussion contains an apparent date typo referring to an evaluation “as of March 31, 2012.”
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer: the provided 10-Q identifies iGambit Inc., not Nutex Health Inc.
- Verify receipt and accounting for Digi-Data’s May 12 payment, including the amount of accrued interest and any remaining receivable balances.
- Assess collectability and timing of the $229,779 IGX rescission receivable and discontinued-operation assets, as well as the related litigation and counterparty risks.
- Review the convertible note’s conversion and reset provisions, derivative valuation assumptions, remaining principal, and dilution reflected in post-quarter share counts.
- Monitor Gotham’s concentrated customer exposure, revenue transition, cash burn, and the company’s ability to obtain financing for growth or acquisitions.